Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award PDF Print E-mail
Thursday, 17 September 2009 10:52
In a recent Medical News Today article, it was reported that Thomas A. Medsger Jr., M.D.,  Gerald P. Rodnan Professor of Medicine, University of Pittsburgh School of Medicine, received the Scleroderma Foundation's Lifetime Achievement Award in recognition of his service to the Scleroderma community. The award is the foundation's highest honor and is presented to individuals who have devoted a minimum of 20 years of service, either as a volunteer or professional, to the Scleroderma community.

Dr. Medsger has served as chief of the University of Pittsburgh's Division of Rheumatology and Clinical Immunology, and director of the Scleroderma Research Program and UPMC's Scleroderma Clinic. His primary clinical and investigative interest is in Scleroderma and other connective tissue diseases.

In 2001 and 2005, Dr. Medsger was the recipient of the Scleroderma Foundation's Doctor of the Year award. He also has been designated as one of the Best Doctors in America by American Health Magazine for the past two decades and was the recipient of the American College of Rheumatology's Distinguished Rheumatologist Award. Recently, he had the title of "Master" conferred upon him by the American College of Rheumatology - a title awarded to members of high professional competence, ethics and moral standing who have significantly furthered the science of rheumatology.

Dr. Medsger currently serves as the Scleroderma Foundation Western Pennsylvania Chapter's treasurer and interim president. He has written numerous articles for the Foundation's Voice magazine and has published more than 300 journal articles about scleroderma and related diseases.

Read the full article here.
 
More articles :

» Our First Year Anniversary

Celebrating an important anniversary is always a blessing. The Scleroderma Care Foundation was officially incorporated on 15th October 2008. Its mission to provide support and education for persons afflicted with within Trinidad and Tobago became a...

» Moves Toward Personalized Medicine for Scleroderma

researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study , an autoimmune disease for which there currently is no...

» Silicone and Scleroderma Revisited

Silicone, a synthetic polymer considered to be a biologically inert substance, is used in a multitude of medical products, the most publicly recognized of which are breast implants. Silicone breast implants have been in use since the early 1960s for...

» Positive Phase II Results for AIMSPRO In Scleroderma Announced

announced yesterday, positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic...

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Scleroderma in Children: Emerging Management Issues

Saumya PandaDepartment of Dermatology, KPC Medical College, Kolkata, IndiaDate of Web Publication: 21-Jul-2010Abstract         Scleroderma is a set of rare connective tissue diseases of unknown etiology. It is...